1-20 of 26
Ira Pastan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin

Available to Purchase
Anirban Chakraborty, Masanori Onda, Tara O’Shea, Junxia Wei, Xiufen Liu, Tapan K. Bera, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (7): 1021–1030.
https://doi.org/10.1158/1535-7163.MCT-23-0233
Published: 02 July 2024
View articletitled, A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin
Open the PDF for A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin in another window
Includes: Supplementary data
Journal Articles

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

Open Access
Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho, Raffit Hassan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (7): 1195–1206.
https://doi.org/10.1158/1535-7163.MCT-22-0073
Published: 05 July 2022
View articletitled, Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
Open the PDF for Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors in another window
Includes: Supplementary data
Journal Articles

GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling

Available to Purchase
Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D. Hall, Min Qian, Ira Pastan, Mitchell Ho
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 960–973.
https://doi.org/10.1158/1535-7163.MCT-21-0778
Published: 01 June 2022
View articletitled, GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling
Open the PDF for GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling in another window
Includes: Supplementary data
Journal Articles

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Available to Purchase
Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (3): 812–821.
https://doi.org/10.1158/1535-7163.MCT-19-0890
Published: 02 March 2020
View articletitled, Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Open the PDF for Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Free
Christine Alewine, Mehwish Iqra Ahmad, Cody J Peer, Seth Steinberg, William D Figg, Raffit Hassan, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A081.
https://doi.org/10.1158/1535-7163.TARG-19-A081
Published: 01 December 2019
View articletitled, Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion
Journal Articles

Abstract CN07-03: Recombinant immunotoxins for hematologic malignancies

Free
Robert Kreitman, Daniel Gorelik, Maryalice Stetler-Stevenson, Constance M Yuan, Hao-Wei Wang, Hong Zhou, Katherine Potocka, Erin Fykes, Evgeny Arons, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): CN07-03.
https://doi.org/10.1158/1535-7163.TARG-19-CN07-03
Published: 01 December 2019
View articletitled, Abstract CN07-03: Recombinant immunotoxins for hematologic malignancies
Journal Articles

Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer

Free
Mitchell Ho, Bryan D Fleming, Tim F Greten, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): CN07-02.
https://doi.org/10.1158/1535-7163.TARG-19-CN07-02
Published: 01 December 2019
View articletitled, Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer
Journal Articles

Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering

Free
Gilad Kaplan, Ronit Mazor, Fred Lee, Youjin Jang, Yasmin Leshem, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (7): 1486–1493.
https://doi.org/10.1158/1535-7163.MCT-17-1041
Published: 01 July 2018
View articletitled, Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering
Open the PDF for Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering in another window
Includes: Supplementary data
Journal Articles

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

Free
Prince Awuah, Tapan K. Bera, Messan Folivi, Oleg Chertov, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1648–1655.
https://doi.org/10.1158/1535-7163.MCT-15-0863
Published: 05 July 2016
View articletitled, Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins
Open the PDF for Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins in another window
Includes: Supplementary data
Journal Articles

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins

Free
Xiufen Liu, Fabian Müller, Alan S. Wayne, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (5): 1053–1062.
https://doi.org/10.1158/1535-7163.MCT-15-0828
Published: 05 May 2016
View articletitled, Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins
Open the PDF for Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins in another window
Includes: Supplementary data
Journal Articles

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Free
Ronit Mazor, Jingli Zhang, Laiman Xiang, Selamawit Addissie, Prince Awuah, Richard Beers, Raffit Hassan, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2789–2796.
https://doi.org/10.1158/1535-7163.MCT-15-0532
Published: 06 December 2015
View articletitled, Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors
Open the PDF for Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract A157: Multi-kinase inhibitor H89 enhances activity of pseudomonas exotoxin-based immunotoxins targeting acute lymphoblastic leukemia

Free
Fabian Mueller, Xiu Fen Liu, Alan S. Wayne, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A157.
https://doi.org/10.1158/1535-7163.TARG-15-A157
Published: 01 December 2015
View articletitled, Abstract A157: Multi-kinase inhibitor H89 enhances activity of pseudomonas exotoxin-based immunotoxins targeting acute lymphoblastic leukemia
Journal Articles

Abstract C163: Understanding the mechanism for synergistic anti-tumor activity of a meosthelin-targeted immunotoxin and taxanes

Free
Christine Campo Alewine, Emily Kolyvas, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C163.
https://doi.org/10.1158/1535-7163.TARG-15-C163
Published: 01 December 2015
View articletitled, Abstract C163: Understanding the mechanism for synergistic anti-tumor activity of a meosthelin-targeted immunotoxin and taxanes
Journal Articles

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

Free
Christine Alewine, Laiman Xiang, Takao Yamori, Gerhard Niederfellner, Klaus Bosslet, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (11): 2653–2661.
https://doi.org/10.1158/1535-7163.MCT-14-0132
Published: 03 November 2014
View articletitled, Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Open the PDF for Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers in another window
Includes: Supplementary data
Journal Articles

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

Free
Kevin Hollevoet, Emily Mason-Osann, Xiu-fen Liu, Sabine Imhof-Jung, Gerhard Niederfellner, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (8): 2040–2049.
https://doi.org/10.1158/1535-7163.MCT-14-0089-T
Published: 05 August 2014
View articletitled, In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Open the PDF for In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors

Free
Xiu-Fen Liu, Laiman Xiang, David J. FitzGerald, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (1): 82–89.
https://doi.org/10.1158/1535-7163.MCT-13-0726
Published: 13 January 2014
View articletitled, Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors
Open the PDF for Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

Free
John E. Weldon, Laiman Xiang, Jingli Zhang, Richard Beers, Dawn A. Walker, Masanori Onda, Raffit Hassan, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (1): 48–57.
https://doi.org/10.1158/1535-7163.MCT-12-0336
Published: 13 January 2013
View articletitled, A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
Open the PDF for A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity in another window
Includes: Supplementary data
Journal Articles

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Free
Ronan J. Kelly, Elad Sharon, Ira Pastan, Raffit Hassan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 517–525.
https://doi.org/10.1158/1535-7163.MCT-11-0454
Published: 06 March 2012
View articletitled, Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
Open the PDF for Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development in another window
Journal Articles

Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38

Free
Neal Luther, Nai-Kong Cheung, Eleni P. Souliopoulos, Ioannis Karempelas, Daniel Bassiri, Mark A. Edgar, Hong-fen Guo, Ira Pastan, Philip H. Gutin, Mark M. Souweidane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (4): 1039–1046.
https://doi.org/10.1158/1535-7163.MCT-09-0996
Published: 07 April 2010
View articletitled, Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38
Open the PDF for Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38 in another window
Journal Articles

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity

Free
Yang Feng, Xiaodong Xiao, Zhongyu Zhu, Emily Streaker, Mitchell Ho, Ira Pastan, Dimiter S. Dimitrov
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (5): 1113–1118.
https://doi.org/10.1158/1535-7163.MCT-08-0945
Published: 13 May 2009
View articletitled, A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
Open the PDF for A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity in another window